SciSparc Ltd. (SPRC)
SPRC Stock Price Chart
Explore SciSparc Ltd. interactive price chart. Choose custom timeframes to analyze SPRC price movements and trends.
SPRC Company Profile
Discover essential business fundamentals and corporate details for SciSparc Ltd. (SPRC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Aug 2021
Employees
2.00
Website
https://scisparc.comCEO
Oz Adler
Description
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
SPRC Financial Timeline
Browse a chronological timeline of SciSparc Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 23 Apr 2026
EPS came in at -$0.70 , while revenue for the quarter reached $395.00k .
Stock split effective on 4 Mar 2026
Shares were split 1 : 9 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 24 Jul 2025
EPS came in at -$161.28 , while revenue for the quarter reached $461.00k .
Stock split effective on 3 Jul 2025
Shares were split 1 : 21 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 24 Apr 2025
EPS came in at -$12.63 , while revenue for the quarter reached $466.00k .
Earnings released on 1 Jul 2024
EPS came in at -$15.30 , while revenue for the quarter reached $840.00k .
Earnings released on 6 May 2024
EPS came in at -$7.33 , while revenue for the quarter reached $907.00k .
Stock split effective on 28 Sept 2023
Shares were split 1 : 26 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Aug 2023
EPS came in at -$19.53 , while revenue for the quarter reached $1.97m .
Earnings released on 27 Apr 2023
EPS came in at $24.90 , while revenue for the quarter reached $1.35m .
Earnings released on 28 Jul 2022
EPS came in at -$42.12 .
Earnings released on 4 Apr 2022
EPS came in at -$31.20 , while revenue for the quarter reached $1.07m .
Earnings released on 26 Aug 2021
EPS came in at -$35.57 .
SPRC Stock Performance
Access detailed SPRC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
